
Patient recruitment remains one of the most persistent operational challenges in clinical research.
A protocol may be scientifically sound. Regulatory
approvals may be obtained. Sites may be activated. Investigators may be
enthusiastic.
Yet enrollment may still fall significantly below
expectations.
The immediate response is often familiar:
Open more sites. Add more countries. Increase
recruitment activities. Extend the timeline.
These measures can sometimes help.
But they do not necessarily address the underlying
problem.
In many cases, recruitment difficulties are not
created when enrollment begins. They originate during protocol development,
feasibility assessment, site selection and study planning.
For sponsors, the most important question is therefore
not simply:
How can we recruit more participants?
It is:
What could prevent the right participants from
entering and remaining in this trial—and how early can we address those
barriers?
1. Recruitment Failure Is a Scientific and Operational
Problem
Recruitment difficulties have consequences beyond
delayed milestones.
A retrospective analysis by Kasenda and colleagues
examined 1,017 randomized clinical trials approved by research ethics
committees in several countries. Approximately one-quarter were discontinued
prematurely, with poor recruitment the most frequently reported reason for
discontinuation [1].
When trials fail to recruit adequately, the
consequences may include:
- Insufficient statistical power
- Delayed development timelines
- Increased operational expenditure
- Reduced precision of treatment-effect estimates
- Inconclusive study results
- Wasted investigator and participant contributions
Recruitment is therefore not simply a
project-management metric.
It is connected to the scientific validity and ethical
value of clinical research.
2. Disease Prevalence Does Not Equal Recruitable
Population
A common feasibility mistake is assuming that the
number of patients with a disease represents the number of participants
available for a study.
Consider a hypothetical hospital managing 1,000
patients annually with a particular condition.
After applying the protocol:
- 400 may have the required disease stage.
- 200 may satisfy previous-treatment criteria.
- 100 may meet laboratory requirements.
- 60 may have no relevant exclusion criteria.
- 35 may be available during the recruitment
period.
- 20 may agree to participate.
- 15 may ultimately be enrolled.
These numbers are illustrative, but the principle is
important.
Available patients ≠ eligible patients ≠ recruitable
patients ≠ enrolled participants.
Sponsors need realistic patient funnels supported by
clinical and site-level evidence.
3. Protocol Complexity Can Reduce Recruitment
Eligibility criteria are intended to protect
participants and support interpretable results.
However, unnecessarily restrictive criteria may limit
access without adding proportional scientific value.
Other design features can create additional barriers:
- Frequent hospital visits
- Extensive laboratory testing
- Long assessment days
- Complex treatment schedules
- Prolonged follow-up
- Restrictive concomitant medication requirements
- Inconvenient assessment windows
ICH E8(R1) encourages sponsors to identify factors
critical to quality during study design and consider the feasibility of trial
procedures [2].
Recruitment feasibility should therefore be assessed
before protocol finalization, not only after the protocol has been approved.
4. Investigator Estimates Need Validation
Investigators provide essential knowledge of their
patient populations.
But estimated recruitment capacity should be evaluated
systematically.
When an investigator predicts enrollment of five
participants per month, sponsors should ask:
How many potentially eligible patients were seen
historically?
How many satisfy the major eligibility criteria?
How many competing trials are recruiting?
How frequently are suitable patients referred?
What was the site's previous enrollment performance?
Does the site have sufficient research staff?
An optimistic estimate is not necessarily an
inaccurate estimate.
However, it should be treated as an assumption
requiring supporting evidence.
5. Competing Trials Can Change the Recruitment
Landscape
A site may have substantial access to the target
population but be involved in several competing studies.
These studies may offer:
- Broader eligibility
- Fewer procedures
- Different investigational treatments
- More convenient schedules
- Alternative treatment options
Competition may also change after feasibility has been
completed.
Sponsors should therefore reassess recruitment
assumptions when new trials enter the same therapeutic area.
Feasibility is a continuing activity, not a single
questionnaire completed during study start-up.
6. Site Resources Matter as Much as Patient Access
A principal investigator may have excellent clinical
expertise and access to patients.
But recruitment depends on the wider site team.
Clinical Research Coordinators, research nurses,
pharmacists, laboratory personnel and administrative teams contribute to
screening, scheduling, consent coordination, treatment and follow-up.
A site with inadequate CRC capacity may struggle even
when eligible patients are available.
Sponsors should assess:
- Research staffing
- Competing workload
- Investigator availability
- Screening procedures
- Referral coordination
- Data-entry capacity
- Participant follow-up resources
The objective is to identify sites capable of
converting realistic patient access into reliable trial participation.
7. Patient Burden Must Be Evaluated
Patients do not make participation decisions solely on
scientific eligibility.
They may consider:
Travel distance
Time away from employment
Caregiving responsibilities
Visit duration
Additional procedures
Potential adverse effects
Financial implications
Uncertainty about treatment
Recruitment strategies should therefore include
appropriate patient-facing communication and practical measures to reduce
unnecessary burden.
Depending on the study and applicable requirements,
these may include flexible scheduling, appropriate reimbursement, local
assessments or decentralized trial elements.
Such measures must remain consistent with the
protocol, ethical requirements and participant protection.
8. Retention Is Part of Recruitment Planning
Recruitment targets are meaningful only if the study
can retain enough participants to generate interpretable evidence.
A trial may meet its enrollment target but still
experience substantial missing outcome data because participants discontinue
follow-up.
Sponsors should therefore distinguish between:
Enrollment
Treatment adherence
Treatment discontinuation
Study withdrawal
Loss to follow-up
These are not interchangeable outcomes.
A participant who stops investigational treatment may
still be able to contribute valuable follow-up information, subject to consent
and the protocol.
Retention planning should begin during study design.
9. Recruitment Forecasts Should Be Updated Using
Actual Performance
Once recruitment begins, sponsors should compare
assumptions with reality.
Useful indicators include:
- Actual versus projected screening
- Screen-failure rates
- Enrollment per active site
- Time from activation to first participant
- Recruitment by country
- Participant withdrawal
- Referral conversion
- Site staffing changes
However, metrics need interpretation.
A high screen-failure rate may indicate overly
optimistic feasibility, a restrictive protocol or a deliberate screening
strategy.
The cause determines the intervention.
10. Why Opening More Sites Is Not Always the Answer
Adding sites increases operational complexity and
cost.
It may require additional:
- Regulatory and ethics submissions
- Contracting
- Monitoring
- Investigational product supply
- Training
- Vendor coordination
- Quality oversight
If the underlying problem is an excessively
restrictive protocol, opening more sites may simply reproduce the same problem
across a larger network.
Sponsors should first identify whether the recruitment
barrier is:
Protocol-related
Population-related
Site-related
Operational
Competitive
Participant-related
Only then should corrective action be selected.
11. A Practical Recruitment Risk Framework for
Sponsors
Before activating sites, sponsors should evaluate five
dimensions.
1. Population: Is the eligible population
supported by evidence?
2. Access: Can the proposed sites realistically reach those
patients?
3. Participation: Can patients reasonably
undertake the study procedures?
4. Delivery: Do sites have the staff and infrastructure to recruit
and retain participants?
5. Timeline: Will sites activate early enough to contribute
meaningfully?
During the trial, these assumptions should be reviewed
against observed performance.
This creates a continuous process:
Feasibility → Recruitment → Performance Review → Root
Cause Assessment → Targeted Intervention
The Agile Clinical Trendz Perspective
At Agile Clinical Trendz, we believe
recruitment planning should begin before site activation and remain connected
to clinical operations, feasibility, data management and study governance.
Effective recruitment strategies require:
- Evidence-based feasibility
- Realistic patient-population estimates
- Appropriate site selection
- Early identification of protocol barriers
- Adequate CRC and investigator capacity
- Participant-centered study execution
- Continuous performance review
The objective is not simply to recruit faster.
It is to recruit appropriately, retain participants
wherever possible and generate the evidence needed to answer the study's
scientific question.
The best recruitment strategy is not the one that
reacts fastest to delays. It is the one that identifies preventable barriers
before they become delays.
References
- Kasenda B, von Elm E, You J, et al. Prevalence,
characteristics, and publication of discontinued randomized trials. JAMA.
2014;311(10):1045–1051. doi:10.1001/jama.2014.1361.
- International Council for Harmonisation. ICH
E8(R1): General Considerations for Clinical Studies. 2021.
- International Council for Harmonisation. ICH
E6(R3): Guideline for Good Clinical Practice. 2025.
- Huang GD, Bull J, Johnston McKee K, et al.
Clinical trials recruitment planning: A proposed framework from the
Clinical Trials Transformation Initiative. Contemporary Clinical Trials.
2018;66:74–79. doi:10.1016/j.cct.2018.01.003.
- Treweek S, Pitkethly M, Cook J, et al. Strategies
to improve recruitment to randomised trials. Cochrane Database of
Systematic Reviews. 2018;(2). doi:10.1002/14651858.MR000013.pub6.